These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8854508)

  • 1. The FDA and regulation of cost-effectiveness claims.
    Neumann PJ; Zinner DE; Paltiel AD
    Health Aff (Millwood); 1996; 15(3):54-71. PubMed ID: 8854508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
    Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
    Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceuticals: drug importation--2005. End of Year Issue Brief.
    Varma P; Seay M
    Issue Brief Health Policy Track Serv; 2005 Dec; ():1-20. PubMed ID: 16708457
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.
    Woo KS; White HD
    Pharmacoeconomics; 1993 Mar; 3(3):192-204. PubMed ID: 10172049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Myth of the Free Market for Pharmaceuticals.
    Conti RM; Frank RG; Cutler DM
    N Engl J Med; 2024 Apr; 390(16):1448-1450. PubMed ID: 38647106
    [No Abstract]   [Full Text] [Related]  

  • 6. A prescription for change.
    Testoni M
    Healthc Financ Manage; 2015 Oct; 69(10):30, 32. PubMed ID: 26595972
    [No Abstract]   [Full Text] [Related]  

  • 7. Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase.
    Massel D
    Can J Cardiol; 1999 Feb; 15(2):173-9. PubMed ID: 10079776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is alteplase (t-PA) more cost-effective than streptokinase?
    Sanchez LA
    Pharmacoeconomics; 1992 Nov; 2(5):427-8. PubMed ID: 10172065
    [No Abstract]   [Full Text] [Related]  

  • 9. Proposal To Use VA Price As a Benchmark Is off the Mark.
    Kirkner RM
    Manag Care; 2016 Dec; 25(12):14-15. PubMed ID: 28121548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HHS defends expanded 340B drug discounts.
    Lee J
    Mod Healthc; 2014 Jun; 44(24):9. PubMed ID: 25137989
    [No Abstract]   [Full Text] [Related]  

  • 12. Dilemmas in regulation of the market for pharmaceuticals.
    Maynard A; Bloor K
    Health Aff (Millwood); 2003; 22(3):31-41. PubMed ID: 12757269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMCP Seeks an End to 20 Years Of Confusion Over FDAMA Section 114.
    Dalzell MD
    Manag Care; 2016 Sep; 25(9):43-45. PubMed ID: 28121576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study assigns dollar value to alteplase-streptokinase debate.
    Am J Health Syst Pharm; 1995 Aug; 52(15):1600. PubMed ID: 7583819
    [No Abstract]   [Full Text] [Related]  

  • 16. Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy.
    Califf RM; Stump D; Topol EJ; Mark DB
    Am Heart J; 1999 May; 137(5):S90-3. PubMed ID: 10220606
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceuticals and medical devices: business practices. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448
    [No Abstract]   [Full Text] [Related]  

  • 19. PhRMA sues on 340B orphans.
    Lee J
    Mod Healthc; 2013 Oct; 43(40):17. PubMed ID: 24340726
    [No Abstract]   [Full Text] [Related]  

  • 20. Built for the road ahead.
    Mansour A
    Healthc Financ Manage; 2015 Oct; 69(10):76-81. PubMed ID: 26595980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.